Sage Therapeutics said that its experimental pill was more effective than a placebo in treating patients with essential tremors, a neurological condition…
[mc4wp_form id="449"]
The tumor-shrinking activity of the company’s drug was minimal but still comparable to early study data from competing TIGIT-targeted drugs in development,…
Revolution Medicine presented updated data to bolster the case for its lead cancer drug — designed to stop tumor growth by throttling…
Natural killer cells, primed with an antibody, induce remissions in patients with advanced blood cancer. Source: STATNEWS.COM…
Fibrogen acknowledged Tuesday that the company has been touting false heart-safety data for its experimental anemia pill for at least two years,…
The Covid-19 vaccines and therapies that are helping to end this pandemic are proof of the enormous power of private drug innovation….
“I do feel vindicated to a great extent,” said former FDA inspector Arie Menachem, who filed a complaint with the Office of…
Delcath Systems said Wednesday that its liver-tumor treatment device achieved the primary goal of a late-stage clinical trial, but questions linger. Source:…
A new federal report concludes that the U.S. government doesn’t have patent rights to the Gilead drug remdesivir, despite investing millions in…
“The way a university transfers technology to industry can be critical in determining affordability and availability of medicines,” said Anmol Gupta of…